Rheumatology Live

09/11/2026

Today, we remember September 11, 2001, and the nearly 3,000 lives lost. We honor the first responders, families, and communities forever changed by that day, and remember the courage and resilience that followed.

09/07/2026

Labor Day is a time to celebrate the contributions and dedication of American workers.

Today, we recognize the rheumatologists, researchers, and health care professionals whose work continues to advance care and improve quality of life for patients living with rheumatic and autoimmune diseases.

Wishing you a safe and happy Labor Day from RheumatologyLive!

07/04/2026

Happy Fourth of July from RheumatologyLive!

As we celebrate Independence Day, we wish our readers, clinicians, researchers, and healthcare professionals a safe and enjoyable holiday. Thank you for your continued dedication to advancing rheumatology care and improving patient outcomes.

05/28/2026

The FDA just approved a label update for J&J's guseulkumab (Tremfya), making it the first IL-23 inhibitor to inhibit structural joint damage in psoriatic arthritis. Read more:

https://hubs.li/Q04jjXtR0

05/25/2026

This Memorial Day, RheumatologyLive honors the brave men and women who gave their lives in service to our country.

We remember their sacrifice and extend our gratitude to all who have served today and always.

05/23/2026

James F. Howard JR, MD, discusses the importance of the FDA expansion of argenx’s efgartigimod alfa (Vyvgart) for all generalized myasthenia gravis subtypes. Watch now:

https://hubs.li/Q04hKYcz0

05/13/2026

New JIA guidance urges early biologics, favors oral methotrexate, adds mental health screening, and reshapes tapering and monitoring. Read more:

03/25/2026

Jack Arnold, MBBS, PhD University of Leeds discusses the growing use of GLP-1 RAs in rheumatology with Rihards Buss, MD, in our latest Joint Ventures episode. Watch the conversation now:

https://hubs.li/Q048njK30

03/24/2026

Ronald F. van Vollenhoven, MD, PhD, discusses 5-year real-world follow-up that show belimumab stays broadly safe in SLE at . Learn more:

Ronald F. van Vollenhoven, MD, PhD, discusses 5-year real-world follow-up that show belimumab stays broadly safe in SLE.

03/19/2026

A decision on SunPharma's tildrakizumab for psoriatic arthritis is expected by the end of October 2026, as per its recent FDA sBLA acceptance. Read more:

The FDA has set a PDUFA of October 29, 2026, for the therapy's application.